---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-006400"
form_type: "8-K"
ticker: "ABUS"
cik: "0001447028"
company_name: "Arbutus Biopharma Corp"
filed_at: "2024-11-15T23:59:59+00:00"
generated_at: "2026-05-29T23:42:16.184330+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Arbutus reports 50% functional cure in HBsAg<1000 IU/mL patients with imdusiran + IFN in Phase 2a

## Summary
- Cohort A1: 50% (3/6) functional cure in HBeAg-negative patients with baseline HBsAg <1000 IU/mL; overall 25% (3/12).
- IM-PROVE II Group C: 23% (3/13) achieved HBsAg loss at Week 48 with imdusiran, VTP-300 and low-dose nivolumab.
- Both regimens generally well-tolerated; no imdusiran/IFN-related SAEs or discontinuations in IM-PROVE I.
- Data to be presented at AASLD The Liver Meeting 2024 on November 18. Corporate presentation updated on website.
- Combination of imdusiran and interferon shows potential for finite curative treatment in chronic HBV.

## SEC filing metadata
- accession: 0001171843-24-006400
- form_type: 8-K
- ticker: ABUS
- cik: 0001447028
- company_name: Arbutus Biopharma Corp
- filed_at: 2024-11-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447028/000117184324006400/0001171843-24-006400-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447028/000117184324006400/f8k_111524.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-006400
- JSON: https://secwatch.observer/filing/0001171843-24-006400.json
- Plain text: https://secwatch.observer/filing/0001171843-24-006400.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.